AI Summary & Key Takeaways
AI InsightDiscussion and Conclusion: Based on studying patients for three months, we determined that a series of three monthly injections of ranibizumab ensured a stati
📌 3 Key Takeaways
Özet
Introduction: This study aimed to compare the response to ranibizumab therapy in naive diabetic macular edema (DME) patients with and without an epiretinal membrane (ERM). Methods: A retrospective chart review was performed on 71 eyes in 71 DME patients. The patients were divided into a DME without ERM [ERM (-)] group (n=34) and DME with ERM [ERM (+)] group (n=37). Best-corrected visual acuity (BCVA), central macular thickness (CMT) and subfoveal choroidal thickness (SFCT) were evaluated. Results: There were no significant differences in age or gender distribution between the patients in the ERM (-) and ERM (+) groups (p=0.052, p=0.96, respectively). In both groups, CMT showed a significant decrease during the first, second and third months (p<0.01 for each in both groups). Therefore, BCVA increased in both groups and made significant gains from the second month (p=0.044 in the ERM (-) group and p=0.006 in the ERM (+) group). CMT and BCVA values did not differ significantly between the ERM (-) and ERM (+) groups in the baseline, first month, second month or third month. In the ERM (-) group, SFCT values decreased significantly as compared to baseline in the first month, second month and third month (p=0.001, p<0.001, p<0.001, respectively). In the ERM (+) group, the first month SFCT value did not change significantly (p=0.389), but it decreased significantly in the second month and third month as compared to baseline (p<0.001, p<0.001, respectively). Discussion and Conclusion: Based on studying patients for three months, we determined that a series of three monthly injections of ranibizumab ensured a stati